莫西沙星治疗对轻中度慢性阻塞性肺疾病急性加重期患者呼吸困难程度、肺功能的影响OA

Objective To study the effect of moxifloxacin on dyspnea and pulmonary function in patients with acute exacerbation of mild to moderate chronic obstructive pulmonary disease(COPD).Methods This study included 69 patients meeting the criteria for acute exacerbation of mild to moderate COPD from our hospital during the period of January to September 2024.Patients were randomized via a random number table,34 patients assigned to the routine group,which were received piperacillin sodium and tazobactam sodium for injection,while the remaining 35 patients in the study group were treated with moxifloxacin hydrochloride and sodium chloride injection.The clinical efficacy,degree of dyspnea(mMRC score),pulmonary function indexes(FVC,FEV1),inflammatory indexes(WBC,CRP),and incidence of adverse reactions(gastrointestinal symptoms,headache,rash)were compared between the two groups.Results The study group demonstrated a significantly higher total treatment effective rate(94.29%)compared to the routine group(85.29%)(P<0.05).After treatment,the degree of dyspnea(mMRC score),pulmonary function indexes(FVC,FEV1)and inflammatory indexes(WBC,CRP)in the two groups were improved compared with those before treatment,with outcomes in the study group being superior to those in the routine group(P<0.05).The study group demonstrated a significantly lower incidence of adverse reactions(5.71%)compared with the conventional group(14.71%)(P<0.05).Conclusion Moxifloxacin is effective in the treatment of patients with mild to moderate acute exacerbation of COPD.It has a positive effect in reducing the degree of dyspnea,improving pulmonary function,inhibiting inflammatory response and reducing the incidence of adverse reactions.